Advanced search
Publication Cover
Expert Opinion on Drug Delivery Volume 4, 2007 - Issue 4
Submit an article Journal homepage
163
Views
56
CrossRef citations to date
0
Altmetric
Review

Antibiological barrier nanovector technology for cancer applications

Jason Sakamoto Chief Operating Officer, Alliance for NanoHealth, 1825 Herman Pressler Street, Suite 537A, Houston, Texas 77030, USA
, PhD,
Ananth Annapragada Associate Professor, Health Information Sciences, The University of Texas at Houston, 7000 Fannin Street, Suite 890, Houston, Texas 77030, USA
, PhD,
Paolo Decuzzi Associate Professor, Universita' degli Studi Magna Græcia, Viale Europa, 88100, Catanzaro, Italy
, PhD &
Mauro Ferrari Professor, Brown Institute of Molecular Medicine, University of Texas Health Science Center in Houston, 1825 Herman Pressler Street, Suite 537D, Houston, Texas 77030 +713 500 2444+713 500 [email protected]; Professor, Experimental Therapeutics, University of Texas M.D. Anderson Cancer Center; Professor, Biomedical Engineering, Rice University
, PhD
Pages 359-369 | Published online: 07 Aug 2007

Bibliography

  • NORTHFELT DW, MARTIN FJ, WORKING P et al.: Doxorubicin encapsulated in liposomes containing surface-bound polyethylene glycol: pharmacokinetics, tumor localization, and safety in patients with AIDS-related Kaposi's sarcoma. J. Clin. Pharmacol. (1996) 36(1):55-63.
  • JAIN RK: Transport of molecules, particles, and cells in solid tumors. Ann. Rev. Biomed. Eng. (1999) 1:241-263.
  • JANG SH, WIENTJES MG, LU D, AU JL: Drug delivery and transport to solid tumors. Pharm. Res. (2003) 20(9):1337-1350.
  • LANKELMA J, DEKKER H, LUQUE FR et al.: Doxorubicin gradients in human breast cancer. Clin. Cancer. Res. (1999) 5(7):1703-1707.
  • TANNOCK IF, LEE CM, TUNGGAL JK, COWAN DS, EGORIN MJ: Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clin. Cancer Res. (2002) 8(3):878-884.
  • BALUK P, HASHIZUME H, MCDONALD DM: Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. (2005) 15(1):102-111.
  • BLUME G, CEVC G: Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta (1990) 1029(1):91-97.
  • GABIZON AA: Stealth liposomes and tumor targeting: one step further in the quest for the magic bullet. Clin. Cancer Res. (2001) 7(2):223-225.
  • PEGRAM M, SLAMON D: Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy. Semin. Oncol. (2000) 27(5 Suppl. 9):13-19.
  • SAKAMOTO JH, SMITH BR, XIE B et al.: The molecular analysis of breast cancer utilizing targeted nanoparticle based ultrasound contrast agents. Technol. Cancer Res. Treat. (2005) 4(6):627-636.
  • SLAMON DJ, LEYLAND-JONES B, SHAK S et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. (2001) 344(11):783-792.
  • DRUKER BJ, TAMURA S, BUCHDUNGER E et al.: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. (1996) 2(5):561-566.
  • DRUKER BJ: Imatinib as a paradigm of targeted therapies. Adv. Cancer Res. (2004) 91:1-30.
  • DRUKER BJ, GUILHOT F, O'BRIEN SG et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. (2006) 355(23):2408-2417.
  • FERRARI M: Nanovector therapeutics. Curr. Opin. Chem. Biol. (2005) 9(4):343-346.
  • FERRARI M: Cancer nanotechnology: opportunities and challenges. Nat. Rev. Cancer (2005) 5(3):161-171.
  • LI KC, PANDIT SD, GUCCIONE S, BEDNARSKI MD: Molecular imaging applications in nanomedicine. Biomed. Microdevices (2004) 6(2):113-116.
  • AKERMAN ME, CHAN WC, LAAKKONEN P, BHATIA SN, RUOSLAHTI E: Nanocrystal targeting in vivo. Proc. Natl. Acad. Sci. USA (2002) 99(20):12617-12621.
  • LI L, WARTCHOW CA, DANTHI SN et al.: A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58(4):1215-1227.
  • PAN D, TURNER JL, WOOLEY KL: Folic acid-conjugated nanostructured materials designed for cancer cell targeting. Chem. Commun. (Camb) (2003) (19):2400-2401.
  • PIROLLO K, XU L, CHANG E: Immunoliposomes: a Targeted Delivery Tool for Cancer Treatment. Curiel D (Ed.), Wiley-Liss (2002).
  • QUINTANA A, RACZKA E, PIEHLER L et al.: Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. (2002) 19(9):1310-1316.
  • WINTER PM, CARUTHERS SD, KASSNER A et al.: Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel α(nu)β3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer. Res. (2003) 63(18):5838-5843.
  • DELLIAN M, YUAN F, TRUBETSKOY VS, TORCHILIN VP, JAIN RK: Vascular permeability in a human tumour xenograft: molecular charge dependence. Br. J. Cancer (2000) 82(9):1513-1518.
  • JULIANO RL, STAMP D: Effect of particle-size and charge on clearance rates of liposomes and liposome encapsulated drugs. Biochem. Bioph. Res. Co. (1975) 63(3):651-658.
  • DECUZZI P, FERRARI M: The role of specific and non-specific interactions in receptor-mediated endocytosis of nanoparticles. Biomaterials (2007) 28:2915-2922.
  • SANGA S, SINEK JP, FRIEBOES HB et al.: Mathematical modeling of cancer progression and response to chemotherapy. Expert. Rev. Anticancer. Ther. (2006) 6(10):1361-1376.
  • CHARNAY C, LEE A, MAN SQ et al.: Reduced symmetry metallodielectric nanoparticles: chemical synthesis and plasmonic properties. J. Phys. Chem. B (2003) 107(30):7327-7333.
  • HIRSCH LR, STAFFORD RJ, BANKSON JA et al.: Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc. Natl. Acad. Sci. USA (2003) 100(23):13549-13554.
  • LOO C, LIN A, HIRSCH L et al.: Nanoshell-enabled photonics-based imaging and therapy of cancer. Technol. Cancer. Res. Treat. (2004) 3(1):33-40.
  • O'NEAL DP, HIRSCH LR, HALAS NJ, PAYNE JD, WEST JL: Photo-thermal tumor ablation in mice using near infrared-absorbing nanoparticles. Cancer Lett. (2004) 209(2):171-176.
  • IZZO F, THOMAS R, DELRIO P et al.: Radiofrequency ablation in patients with primary breast carcinoma: a pilot study in 26 patients. Cancer (2001) 92(8):2036-2044.
  • ROY I, OHULCHANSKYY TY, PUDAVAR HE et al.: Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J. Am. Chem. Soc. (2003) 125(26):7860-7865.
  • YAN F, KOPELMAN R: The embedding of meta-tetra(hydroxyphenyl)-chlorin into silica nanoparticle platforms for photodynamic therapy and their singlet oxygen production and pH-dependent optical properties. Photochem. Photobiol. (2003) 78(6):587-591.
  • OYEWUMI MO, MUMPER RJ: Engineering tumor-targeted gadolinium hexanedione nanoparticles for potential application in neutron capture therapy. Bioconjug. Chem. (2002) 13(6):1328-1335.
  • MAY DJ, ALLEN JS, FERRARA KW: Dynamics and fragmentation of thick-shelled microbubbles. IEEE Trans. Ultrason Ferroelectr. Freq. Control (2002) 49(10):1400-1410.
  • BERGEY EJ, LEVY L, WANG XP et al.: DC magnetic field induced magnetocytolysis of cancer cells targeted by LH-RH magnetic nanoparticles in vitro. Biomed. Microdevices (2002) 4(4):293-299.
  • ISHII D, KINBARA K, ISHIDA Y et al.: Chaperonin-mediated stabilization and ATP-triggered release of semiconductor nanoparticles. Nature (2003) 423(6940):628-632.
  • POTINENI A, LYNN DM, LANGER R, AMIJI MM: Poly(ethylene oxide)-modified poly(β-amino ester) nanoparticles as a pH-sensitive biodegradable system for paclitaxel delivery. J. Control Release (2003) 86(2-3):223-234.
  • DUNCAN R: The dawning era of polymer therapeutics. Nat. Rev. Drug Discov. (2003) 2(5):347-360.
  • AIRD WC: Phenotypic heterogeneity of the endothelium: I. Structure, function, and mechanisms. Circ. Res. (2007) 100(2):158-173.
  • NERI D, BICKNELL R: Tumour vascular targeting. Nat. Rev. Cancer (2005) 5(6):436-446.
  • VOLDBORG BR, DAMSTRUP L, SPANG-THOMSEN M, POULSEN HS: Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann. Oncol. (1997) 8(12):1197-1206.
  • WITTE L, HICKLIN DJ, ZHU Z et al.: Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. (1998) 17(2):155-161.
  • BASSETT SE, FENNEWALD SM, KING DJ et al.: Combinatorial selection and edited combinatorial selection of phosphorothioate aptamers targeting human NF-κB RelA/p50 and RelA/RelA. Biochemistry (2004) 43(28):9105-9115.
  • PASQUALINI R, KOIVUNEN E, RUOSLAHTI E: α v integrins as receptors for tumor targeting by circulating ligands. Nat. Biotechnol. (1997) 15(6):542-546.
  • WAUTIER JL, WAUTIER MP: Erythrocyte adhesion to the vascular endothelium. Transfus. Clin. Biol. (1999) 6(6):397-402.
  • AFSHAR-KHARGHAN V, THIAGARAJAN P: Leukocyte adhesion and thrombosis. Curr. Opin. Hematol. (2006) 13(1):34-39.
  • BARUCH D: Platelet–vessel wall interactions. Therapie (2006) 61(5):371-378.
  • ENIOLA AO, HAMMER DA: Characterization of biodegradable drug delivery vehicles with the adhesive properties of leukocytes II: effect of degradation on targeting activity. Biomaterials (2005) 26(6):661-670.
  • KOZIARA JM, LOCKMAN PR, ALLEN DD, MUMPER RJ: In situ blood–brain barrier transport of nanoparticles. Pharm. Res. (2003) 20(11):1772-1778.
  • LOCKMAN PR, MUMPER RJ, KHAN MA, ALLEN DD: Nanoparticle technology for drug delivery across the blood–brain barrier. Drug Dev. Ind. Pharm. (2002) 28(1):1-13.
  • LOCKMAN PR, OYEWUMI MO, KOZIARA JM et al.: Brain uptake of thiamine-coated nanoparticles. J. Control Release (2003) 93(3):271-282.
  • KIRCHER MF, MAHMOOD U, KING RS, WEISSLEDER R, JOSEPHSON L: A multimodal nanoparticle for preoperative magnetic resonance imaging and intraoperative optical brain tumor delineation. Cancer Res. (2003) 63(23):8122-8125.
  • NEUWELT EA, VARALLYAY P, BAGO AG et al.: Imaging of iron oxide nanoparticles by MR and light microscopy in patients with malignant brain tumours. Neuropathol. Appl. Neurobiol. (2004) 30(5):456-471.
  • STEINIGER SC, KREUTER J, KHALANSKY AS et al.: Chemotherapy of glioblastoma in rats using doxorubicin-loaded nanoparticles. Int. J. Cancer (2004) 109(5):759-767.
  • FERRARI M, FRANK M, GROVE C: Particles for Oral Delivery of Peptides and Proteins. In: USPTO. USA (2002).
  • PARK JW: Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res. (2002) 4(3):95-99.
  • GABIZON A, SHMEEDA H, HOROWITZ AT, ZALIPSKY S: Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv. Drug Deliv. Rev. (2004) 56(8):1177-1192.
  • SAUL JM, ANNAPRAGADA A, NATARAJAN JV, BELLAMKONDA RV: Controlled targeting of liposomal doxorubicin via the folate receptor in vitro. J. Control Release (2003) 92(1-2):49-67.
  • GHAGHADA KB, SAUL J, NATARAJAN JV, BELLAMKONDA RV, ANNAPRAGADA AV: Folate targeting of drug carriers: a mathematical model. J. Control Release (2005) 104(1):113-128.
  • SAUL JM, ANNAPRAGADA AV, BELLAMKONDA RV: A dual-ligand approach for enhancing targeting selectivity of therapeutic nanocarriers. J. Control Release (2006) 114(3):277-287.
  • GOREN D, HOROWITZ AT, TZEMACH D et al.: Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump. Clin. Cancer Res. (2000) 6(5):1949-1957.
  • MAJOROS IJ, MYC A, THOMAS T, MEHTA CB, BAKER JR: PAMAM dendrimer-based multifunctional conjugate for cancer therapy: synthesis, characterization, and functionality. Biomacromolecules (2006) 7(2):572-579.
  • COHEN MH, MELNIK K, BOIARSKI AA, FERRARI M, MARTIN FJ: Microfabrication of silicon-based nanoporous particulates for medical applications. Biomed. Microdevices (2003) 5(3):253-259.
  • ROLLAND JP, MAYNOR BW, EULISS LE et al.: Direct fabrication and harvesting of monodisperse, shape-specific nanobiomaterials. J. Am. Chem. Soc. (2005) 127(28):10096-10100.
  • VAN DILLEN T, VAN BLAADEREN A, POLMAN A: Ion beam shaping of colloidal assemblies. Materials Today (2004):40-46.
  • KOHLI P, MARTIN CR: Smart nanotubes for biotechnology. Curr. Pharm. Biotechnol. (2005) 6(1):35-47.
  • JAIN TK, MORALES MA, SAHOO SK, LESLIE-PELECKY DL, LABHASETWAR V: Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol. Pharm. (2005) 2(3):194-205.
  • MANCHESTER M, SINGH P: Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv. Drug Deliv. Rev. (2006) 58(14):1505-1522.
  • SAKHALKAR HS, DALAL MK, SALEM AK et al.: Leukocyte-inspired biodegradable particles that selectively and avidly adhere to inflamed endothelium in vitro and in vivo. Proc. Natl. Acad. Sci. USA (2003) 100(26):15895-15900.
  • SIMBERG D, DUZA T, PARK JH et al.: Biomimetic amplification of nanoparticle homing to tumors. Proc. Natl. Acad. Sci. USA (2007) 104(3):932-936.
  • YANG X, WANG H, BEASLEY DW et al.: Selection of thioaptamers for diagnostics and therapeutics. Ann. NY Acad. Sci. (2006) 1082:116-119.
  • FAROKHZAD OC, KARP JM, LANGER R: Nanoparticle-aptamer bioconjugates for cancer targeting. Expert Opin. Drug Deliv. (2006) 3(3):311-324.
  • TATEISHI N, SUZUKI Y, SOUTANI M, MAEDA N: Flow dynamics of erythrocytes in microvessels of isolated rabbit mesentery: cell-free layer and flow resistance. J. Biomech. (1994) 27(9):1119-1125.
  • GAVZE E, SHAPIRO M: Motion of inertial spheroidal particles in a shear flow near a solid wall with special application to aerosol transport in microgravity. J. Fluid. Mech. (1998) 371:59-79.
  • PIERRES A, BENOLIEL AM, ZHU C, BONGRAND P: Diffusion of microspheres in shear flow near a wall: Use to measure binding rates between attached molecules. Biophysical. J. (2001) 81(1):25-42.
  • DECUZZI P, FERRARI M: The adhesive strength of non-spherical particles mediated by specific interactions. Biomaterials (2006) 27(30):5307-5314.
  • MCDONALD DM, BALUK P: Significance of blood vessel leakiness in cancer. Cancer Res. (2002) 62(18):5381-5385.
  • HASHIZUME H, BALUK P, MORIKAWA S et al.: Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. (2000) 156(4):1363-1380.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.